|
Index | - | P/E | - | EPS (ttm) | -1.40 | Insider Own | 10.10% | Shs Outstand | 25.26M | Perf Week | -5.73% |
Market Cap | 139.36M | Forward P/E | - | EPS next Y | -2.10 | Insider Trans | 0.00% | Shs Float | 25.20M | Perf Month | -26.00% |
Income | -34.80M | PEG | - | EPS next Q | -0.46 | Inst Own | 52.50% | Short Float | 0.19% | Perf Quarter | -53.75% |
Sales | - | P/S | - | EPS this Y | 19.40% | Inst Trans | - | Short Ratio | 1.38 | Perf Half Y | - |
Book/sh | 6.55 | P/B | 0.90 | EPS next Y | 56.30% | ROA | - | Target Price | - | Perf Year | - |
Cash/sh | 6.95 | P/C | 0.85 | EPS next 5Y | 47.60% | ROE | - | 52W Range | 5.77 - 17.99 | Perf YTD | -52.68% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -67.09% | Beta | - |
Dividend % | - | Quick Ratio | 30.40 | Sales past 5Y | - | Gross Margin | - | 52W Low | 2.60% | ATR | 0.47 |
Employees | 28 | Current Ratio | 30.40 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 28.24 | Volatility | 7.45% 6.73% |
Optionable | No | Debt/Eq | 0.00 | EPS Q/Q | 30.60% | Profit Margin | - | Rel Volume | 4.88 | Prev Close | 6.12 |
Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | Mar 29 BMO | Payout | - | Avg Volume | 34.73K | Price | 5.92 |
Recom | 1.20 | SMA20 | -7.05% | SMA50 | -35.20% | SMA200 | -50.62% | Volume | 169,365 | Change | -3.27% |
![]() | ||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of cancer and fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark. | ||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite